Printer Friendly

CYTEL ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER

 CYTEL ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER
 SAN DIEGO, Dec. 10 /PRNewswire/ -- Cytel Corporation (NASDAQ: CYTL)


today announced the resignation of Kenneth J. Collins, executive vice president of finance and administration, chief financial officer and director. Collins is leaving Cytel to rejoin Synergen, Inc., as vice president, finance and administration, a position he previously held at the company for nine years prior to joining Cytel in August 1991.
 Commenting on his decision to leave Cytel, Collins said, "I chose to leave Cytel for personal reasons. My family and I truly missed our lifestyle in Colorado and long established relationships with colleagues at Synergen. My brief working experience at Cytel was fulfilling and I regret that I will not be a part of Cytel's exciting future."
 "We were pleased to have an executive with Ken's experience in the biotechnology industry join Cytel and are saddened by his decision to depart," said Jay D. Kranzler, M.D., Ph.D., president and CEO at Cytel. "We wish him much future success."
 Cytel, founded in 1987, is a leader in the discovery and design of a new class of drugs which may be more effective in treating immune system disorders and inflammatory diseases than drugs currently on the market. The design of these immunotherapeutics is based on Cytel's discoveries of specific immune receptors known to be critical in the early stages of the immune response and an advanced understanding of the receptors' role in the molecular events controlling the immune response and inflammation. The company raised $52 million through a public offering of four million shares in November 1991.
 -0- 12/10/91
 /CONTACT: Jay D. Kranzler, president and CEO of Cytel, 619-552-3010; or Karen Bergman of Burns McClellan, 212-545-1919, for Cytel/
 (CYTL) CO: Cytel Corporation ST: California IN: MTC SU: PER


GK-SH -- NY008 -- 0847 12/10/91 08:40 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 10, 1991
Words:307
Previous Article:HEINZ ANNOUNCES SECOND QUARTER RESULTS
Next Article:LUKENS SHIPS 11,500 TONS DURING WEEK OF DEC. 2
Topics:


Related Articles
Cytel Software Releases StatXact(R) Version 6, With Cytel Studio(TM); -- Statistical software for exact nonparametric inference --.
Cytel Software Announces Ranganath Nayak as CEO and Steve Herbert as VP Sales and Business Development.
Jerald S. Schindler Named President of Cytel Pharmaceutical Research Division.
Cytel Inc. Appoints New CFO John Hallinan.
SGX Pharmaceuticals Elects Karin Eastham to Board of Directors.
Cytel Experts Present Latest Advances in Adaptive Clinical Trials at DIA Annual Meeting.
Irving Dark Named Vice President of Cytel Clinical Research Services.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters